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The preparation of a reagent capable of reversibly attaching polyethylene glycol to proteins and the use 
of this material in modifying the plasminogen activators urokinase- and tissue-type plasminogen activator 
are described. The characterisation and the reversible nature of these protein-polymer conjugates are dis- 
cussed, and some of the in vitro properties of these modified enzymes are explored. 
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1. INTRODUCTION 
Conjugation to the periphery of proteins with 
polyethylene glycol and other water-soluble pro- 
teins has proved to be a valuable way of inhibiting 
interactions with other macromolecules, thereby 
conferring on the protein advantages such as 
greater in vivo half-life and reduced susceptibility 
to proteases. Beneficial effects with respect to im- 
munogenicity have also been exploited [l-6]. 
Where such conjugation has been applied to en- 
zymes, it has been more successful with those that 
act on low molecular mass compounds [ 1,3], as 
presumably steric hindrance exercises an adverse 
influence on interaction with larger substrates. For 
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example, in an attempt to moderate the im- 
munogenicity of the streptokinase moiety, 
polyethylene glycol conjugates of streptokinase [7] 
and acylated glasminogen-streptokinase complex 
[8], two plasminogen activators of increasing im- 
portance in thrombolytic therapy, have been 
prepared. Whilst the desired effect of decreased 
immunogenicity was obtained, decreased activity 
was also observed. 
The plasminogen activators of human origin, 
namely tissue-type plasminogen activator (tPA) 
and urokinase (uPA), whilst non-immunogenic in 
man, do suffer from a very rapid rate of elimina- 
tion from the bloodstream [9,10]. A report of an 
irreversibly linked PEG-uPA conjugate [l l] 
showed that the material resided for longer in vivo 
than the parent activator but suggested that a loss 
of activity had occurred. To circumvent the ir- 
reversible losses of activity associated with these 
approaches we have devised a protein-polymer 
linkage which is capable of breaking down in vivo. 
This strategy provides an inactive, relatively slowly 
cleared enzyme which is able to release active 
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Scheme 1. Synthetic scheme for preparation of PEG- 
maleic anhydride reagent. 
material at a reasonable rate thus obviating the 
clinical need to use long infusions, as, for example, 
is currently the therapeutic practice with tPA [12]. 
The reaction of amino groups with substituted 
maleic anhydrides [13,14] has been frequently 
used, especially for sequencing purposes [15). 
Hydrolysis of the maleyl-amino peptide bond is 
facilitated by the neighbouring free carboxyl func- 
tion [ 131. After considering the deacylation 
kinetics of this system [16] we decided to prepare 
reagent (I) which is based on dimethylmaleic 
anhydride. An outline of the synthesis employed is 
given in scheme 1. This paper explores the use of 
this reagent to prepare reversible conjugates and 
reports on some of the properties of such con- 
jugates with the plasminogen activators uPA and 
tPA. 
2. MATERIALS AND METHODS 
2.1. Materials 
Methoxypolyethylene glycol, 5 kDa (Car- 
bowax), was purchased from Union Carbide; other 
chemicals were purchased from Aldrich and used 
without further purification. Benzamidine agarose 
was supplied by Pierce. High molecular mass 
urokinase (uPA) was purchased from Serono 
(Freiburg, FRG). i2’I-UPA was prepared using the 
iodogen method, essentially as described by Fraker 
and Speck [17]. tPA, derived from cultured Bowes 
melanoma cells and purified using affinity 
chromatography on zinc chelate Sepharose and 
lysine Sepharose [181, was kindly supplied by Mr I. 
Dodd. Tripeptide chromogenic substrates S-2444 
(uPA), S-2251 (plasmin) and S-2288 (tPA) were 
obtained from KabiVitrum, Sweden. 
2.2. Preparation of 2-[w-methoxypolyethylene 
(5000) glycoxymethylene]-3-methyl maleic 
anhydride (I) 
(i) 2,3-Dimethylmaleic anhydride was treated 
with two equivalents of N-bromosuccinimide and a 
trace of benzoyl peroxide in boiling carbon 
tetrachloride for 22 h. After filtration, evapora- 
tion and distillation, a material was obtained 
(-40% yield) which was shown by ‘H NMR to be 
about 85% of the desired 2-bromomethyl-3-me- 
thylmaleic anhydride. Traces of dibromide and un- 
brominated material were also found. ‘H NMR 
(CDCl3) 4.1 (2H,s,CHzBr), and 2.2 (3H,s,CH3). 
(ii) To the sodium salt of methoxypolyethyl- 
eneglycol (5000) (from equivalent amounts of 
alcohol and sodium amide) in benzene, was added 
an equimolar amount of the material described 
above. After 22 h at reflux the solution was 
filtered and the product precipitated as a wax (85% 
yield) with petroleum ether. Difference infrared 
spectroscopy showed that this was mainly the title 
compound (Y,,, 1770 cm) as opposed to an 
anhydride ring opened material. Titration of a 
hydrolysed sample of the wax with sodium hy- 
droxide indicated that 1.08 mol anhydride per mol 
of PEG were present. 
2.3. Preparation of 2-fw-methoxypolyethylene 
(5000) glycoxymethyleneJ-3-methyl-maleyl 
conjugates 
2.3.1. uPA 
To a stirred solution of uPA (1.8 mg/ml) and 
12?-uPA (0.2 pCi) in 0.1 M sodium pyrophos- 
phate/HCl, 0.1% (v/v) Tween 80, pH 8.0, buffer 
(buffer P) (0.5 ml) at 0°C was added I (100 mg) 
maintaining the pH at 8.0 by addition of 0.1 M 
NaOH. The material was purified by application 
to a column of benzamidine-Sepharose (9.5 mm x 
11 cm bed weight) equilibrated with 0.1 M NaCl, 
0.05 M NaH2P04/Na2HP04, 0.01% (v/v) Tween 
80, pH 7.4 (PST buffer). After the excess hydro- 
lysed reagent had eluted, the buffer was changed to 
0.5 M arginine, 0.5 M NaCl, 20 mM Tris, pH 7.4 
(ARG buffer), whereupon the modified uPA 
eluted as a single peak (fig.l). The conjugate was 
stored frozen at -40°C. 
2.3.2. tPA 
This reaction was performed in a similar way ex- 
cept that 0.1 M 4-guanidinobutyric acid, a non- 
nucleophilic analogue of arginine which binds to 
tPA, was included with buffer P to aid solubility. 
The material was also gel filtered into PST buffer 
using Sephadex G25M (2 x PD-10 columns, Phar- 
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macia) before application to benzamidine- 
Sepharose. The final material was desalted into 
100 mM NH4HC03, 0.2% D-mannitol using 4 
PD-10 Sephadex G25M columns, and then 
lyophilised. 
2.4. Preparation of dimethylmaleyl-tPA 
To a solution of tPA (-0.35 mg/ml) in buffer P 
(1.0 ml) was added 2.5 M dimethylmaleic 
anhydride (6 x 50 ~1) in dry dioxane at -5 min in- 
tervals to give -140000 equivalents of acylating 
agent. The pH was maintained at 8.0 by periodical 
addition of 0.5 M NaOH. After reaction for a fur- 
ther 15 min the amidolytic activity had fallen to 
zero [ 191. The product was isolated by gel filtration 
of a PD-10 Sephadex G25M column (Pharmacia) 
equilibrated in PST buffer. To a portion 20% 
glycerol was added, and deacylation at 37°C 
monitored by assaying portions against substrate 
S-2288. 
2.5. Plasminogen activation assay 
Into a cuvette was placed 10 mM S-2251 in 
0.1 M triethanolamine buffer, pH 7.0 (25 pl), 
10 mg/ml lys-plasminogen (KabiVitrum, Sweden 
and treated with aprotinin-agarose) (10 ~1) and test 
activator at an appropriate concentration (5 ~1). 
These were added to the cuvette without allowing 
the solutions to mix. To a blank cuvette was added 
the above solutions with the exception of the ac- 
tivator. The assay was initiated by addition of 
0.1 M triethanolamine buffer, pH 8.0 (1 ml), to 
both cuvettes and the A405 (test vs blank) 
monitored. The initial slope of a plot of A against 
time’ was taken as the measure of the rate of 
plasminogen activation. 
2.6. Fibrin plate assays 
Fibrin plate assays were performed essentially as 
described by Granelli-Piperno and Reich [20]. 
2.7. HPLC 
Analytical gel filtration HPLC was performed 
on a column (7.5 x 600 mm) of TSK G3000 SW 
equilibrated with 0.08 M Na2HPOJNaHzP04, 
0.32 M NaCl buffer, pH 7.0, containing 20% 
ethanol [21] using a flow rate of 0.75 ml/min. 
Molecular mass calibration was achieved with 
standard proteins from Biorad (CA, USA). 
3. RESULTS AND DISCUSSION 
The half-life for the return of amidolytic activity 
of dimethylmaleyl tPA, was found to be 42 + 
2 min (SE, n = 4) by S-2288 assay. Consideration 
of the pharmacokinetics and pharmacodynamics 
of thrombolytic agents [22] suggested that this rate 
of regeneration was within a useful range and 
prompted the preparation of polyethylene glycol 
anhydride (I). 
The reaction conditions chosen for the conjuga- 
tions were based on those used for maleic 
anhydride type reactions [13], except that the con- 
centrations of the PEG reagent were fairly low due 
to its high molecular mass. 
Despite this, it was possible to prepare con- 
jugates whose gel filtration molecular masses were 
substantially higher than that of the starting 
materials, being between 130 and 170 kDa. As 
each ethylene glycol moiety is reported to be triply 
hydrated [23,24], the actual molecular mass and 
degree of substitution of the conjugates may be 
somewhat less than these figures suggest. 
Purification of both conjugates was achieved on 
Fig. 1. TSK G30OOSW gel filtration HPLC profiles of (a) 
uPA, (b) the PEG-uPA conjugate, (c) the PEG-uPA 
conjugate after incubation at pH 7.4, 37°C for 72 h in 
0.1 M NaH2POJNa2HP04, 0.1 M NaCI, 0.01% (v/v) 
Tween 80, pH 7.4:glyceroL 4: 1. The apparent 
molecular mass of the conjugate (170 kDa) has almost 
completely reverted to that of free uPA (53 kDa) by this 
treatment. (-) A profile; (O--a) I251 profile. 
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an affinity column of 4-aminobenzamidine 
agarose [25] and gave good recoveries of con- 
jugates well separated from excess reagents (not 
shown). 
Loss of polymer from the PEG-uPA and PEG- 
tPA conjugates showing the reversible nature of 
these materials is shown in figs 1 and 2. The rate 
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Fig.2. TSK G3OOOSW gel filtration HPLC amidolytic 
activity profiles of (a) tPA, the PEG-tPA conjugate 
after incubation at pH 7.4, 37°C for (b) 0, (c) 21 and (d) 
44 h. 
of polymer removal cannot be calculated accurate- 
ly from these data. 
Fig.3 shows the rate of regeneration of func- 
tional enzyme in the plasminogen activation assay 
for the uPA conjugate. The initial activity of this 
conjugate was 44% that of the starting material. 
This process followed approximately first order 
kinetics with a half-life of 6.1 h. The fibrin plate 
assay of this conjugate, which takes -16 h at 
37”C, i.e. at least two half-lives for polymer 
removal, showed that the ratio of the specific 
fibrinolytic activity to the specific amidolytic ac- 
tivity (IU/SU ratio) of the conjugate was identical 
to the starting uPA, again implying that deacyla- 
tion gives the native activator. 
The tPA conjugate was 50-70% as active as un- 
modified activator in the plasminogen activation 
assay. Despite HPLC evidence of polymer removal 
(fig.2), no consistent ime-dependent increase was 
noted possibly due to the instability of tPA under 
the reversing conditions. The fibrin plate activity 
(IU/SU ratio) was 77% that of the native tPA. 
The pharmacokinetic properties of the uPA and 
tPA conjugates have been studied and results sug- 
gest that the PEG-uPA conjugate is cleared in the 
Fig.3. First-order plot of the regeneration of 
plasminogen activating activity of the PEG-uPA 
conjugate upon incubation at pH 7.4, 37°C. 
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guinea pig about lo-times more slowly than un- [6] Kawamura, T., Igarashi, T., Fujii, T., Kamisaki, 
modified uPA [26] and the tPA conjugate about Y., Wada, H. and Kishimoto, S. (1985) Int. Archs 
5-times as slowly as the parent activator (un- Allergy Appl. Immun. 76, 324-330. 
published). [7] Koide, A., Suzuki, S. and Kobayashi, S. (1982) 
In summary, we have demonstrated that reversi- 
ble conjugation of proteins can be achieved with a 
PEG-containing maleic anhydride type reagent. As 
the number of proteins of therapeutic importance 
increases, this is potentially a generally applicable 
and non-toxic method of avoiding or delaying 
undesirable interactions with other macromole- 
cules or cell surfaces, without rendering the protein 
permanently biologically inactive. For each ap- 
plication there will be a different optimum 
regeneration half-life, and it should be possible to 
alter this rate by changing the nature of the 
chemical groups attached to the double bond of 
the maleic anhydride. The scope of this approach 
remains to be fully delineated. 
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